VALBIOTIS is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, VALBIOTIS offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-12 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	€0.7550	-3.21%	79,520
11/09/26	€0.7800	-3.23%	55,075
10/09/26	€0.8060	-0.49%	51,890
09/09/26	€0.8100	-0.49%	42,517
08/09/26	€0.8140	+0.49%	23,881

Real-time Euronext Paris

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7550EUR

Average target price

1.800EUR

Spread / Average Target

+138.41%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris 23:55:00 14/09/2026 HKT			5-day change	1st Jan Change
0.7550 ^EUR	-3.21%		-6.79%	+8.79%

07-23	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
06-29	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT

Market Cap	17.86M 20.61M 16.86M 15.29M 28.69M 1.98B 28.89M 201M 77.57M 1B 77.42M 75.71M 3.19B	P/E 2026 *	-3.28x	P/E 2027 *	-9.44x
Enterprise Value	23.76M 27.42M 22.42M 20.34M 38.16M 2.63B 38.44M 268M 103M 1.33B 103M 101M 4.24B	EV / Sales 2026 *	7.66x	EV / Sales 2027 *	2.25x
Free-Float	97.31%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	ALVAL	Real-time
Börse Stuttgart	8JD	Delayed
CBOE		Real-time
Deutsche Boerse AG	8JD	Delayed
Boerse Muenchen	8JD	Real-time
CBOE		Real-time

07-23	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
06-29	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT
06-27	Valbiotis successfully completes a €10.2m capital increase
06-08	Valbiotis Secures Exclusive Distributor in Qatar	MT
06-08	Valbiotis and Al Danah Medical Company Signs Exclusive Distribution Agreement for Valbiotispro Range in Qatar	CI
06-08	Valbiotis strengthens Middle East presence through Qatar partnership
05-27	Valbiotis SA Announces EU Member States Vote in Favor of Regulation Banning Monacolins From Red Yeast Rice	CI
05-12	Valbiotis shares surge on Asian expansion plans
05-12	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris
05-12	Valbiotis and Aika Form Joint Venture and Establish Subsidiary in Singapore	CI
05-12	Pluxee, Lacroix, Valbiotis... stocks to watch tomorrow in Paris
05-12	Valbiotis continues Asian expansion with the establishment of a Singapore subsidiary
05-11	Valbiotis announces creation by Chinese JV of subsidiary in Singapore	RE

Valbiotis Stock

Stocks

ALVAL

FR0013254851

Biotechnology & Medical Research

Valuation: Valbiotis

Chart: Valbiotis

Latest news: Valbiotis

Analysts' recommendations: Valbiotis

Press Releases: Valbiotis

News in other languages: Valbiotis

Quotes and Performance

Price Extremes

Managers and Directors: Valbiotis

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

05-12	Valbiotis shares surge on Asian expansion plans
30/10/24	Valbiotis: Invest Securities reduces its target
17/07/23	Valbiotis: Invest Securities confirms its recommendation
25/05/23	Valbiotis: Oddo BHF raises its target price
23/05/23	Valbiotis: promising study, Invest Sec. raises its target

07-27	VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission	EQ
07-22	VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63	EQ
06-27	VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M	EQ
06-08	VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%	EQ
06-08	VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East	EQ

07-27	VALBIOTIS SA: Loi sur la prévention cardiovasculaire : Une réponse à un enjeu de santé public majeur Une avancée en pleine cohérence avec la mission de Valbiotis
07-22	VALBIOTIS SA: Les résultats de l’étude clinique REVERSE-IT publiés dans Nature Communications, une reconnaissance scientifique internationale majeure pour l’ingrédient Totum•63
07-22	VALBIOTIS SA: Bilan semestriel du contrat de liquidité.
06-29	Bourse : Ipsen rachète Kartos, Google et Meta se chicanent, Samsung et SK investissent
06-29	Le marché prend une partie de ses bénéfices sur l'IA

1 day	-3.21%
1 week	-6.79%
Current month	-4.43%
1 month	-12.21%
3 months	-15.26%
6 months	-24.50%
Current year	+8.79%

1 week	0.74	0.81
1 month	0.74	0.88
Current year	0.65	1.3
1 year	0.54	1.3
3 years	0.54	7.5
5 years	0.54	7.5
10 years	0.54	10.65

Manager	Title	Age	Since
Sebastien Peltier CEO	Chief Executive Officer	-	-
Stanislas Sordet DFI	Director of Finance/CFO	-	01/03/2024
Pascal Sirvent CTO	Chief Tech/Sci/R&D Officer	-	01/09/2017

Director	Title	Age	Since
Laurent Lévy CHM	Chairman	55	01/03/2017
Jean Zetlaoui BRD	Director/Board Member	-	26/10/2017
Agnès Tixier BRD	Director/Board Member	-	18/03/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/1/22	Jocelyn Pineau	Others	Founder	42,480	0.4364%
28/1/22	Jocelyn Pineau	Exercice	Founder	2,095	0.0215%
10/7/21	Pascal Sirvent	Exercice	Chief Technology Officer	2,000	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALBIOTIS	-3.21%	-6.79%	-7.93%	-84.43%	21.42M
WUXI APPTEC CO., LTD.	+5.04%	+3.27%	+50.62%	+105.43%	66.93B
ARGENX SE	+1.64%	-0.18%	+34.67%	+76.81%	61.97B
INSMED INCORPORATED	-3.18%	-0.78%	-14.14%	+369.82%	28.26B
WUXI BIOLOGICS (CAYMAN) INC.	+4.55%	-0.08%	+34.70%	+17.28%	24.59B
BIONTECH SE	+2.20%	-4.72%	+2.19%	-13.14%	24.3B
GENMAB A/S	+1.15%	-2.26%	+17.56%	-16.53%	19.41B
PHARMAESSENTIA CORPORATION	-7.03%	-9.16%	+161.91%	+303.00%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.44%	-1.68%	-5.00%	+541.17%	14.18B
SUMMIT THERAPEUTICS INC.	+4.96%	+4.63%	-2.75%	+864.40%	14B
Average	+0.96%	-3.73%	+27.18%	+216.38%	27.04B
Weighted average by Cap.	+1.99%	-2.84%	+33.25%	+173.45%

	2026 *	2027 *
Net sales	3.1M 3.58M 2.93M 2.65M 4.98M 343M 5.01M 34.94M 13.46M 174M 13.44M 13.14M 553M	12.8M 14.77M 12.08M 10.96M 20.56M 1.42B 20.71M 144M 55.59M 718M 55.48M 54.26M 2.28B
Net income	-8.2M -9.46M -7.74M -7.02M -13.17M -907M -13.26M -92.42M -35.61M -460M -35.54M -34.76M -1.46B	-2.8M -3.23M -2.64M -2.4M -4.5M -310M -4.53M -31.56M -12.16M -157M -12.14M -11.87M -500M
Net Debt	5.9M 6.81M 5.57M 5.05M 9.48M 653M 9.54M 66.5M 25.62M 331M 25.57M 25.01M 1.05B	10.9M 12.58M 10.29M 9.33M 17.51M 1.21B 17.63M 123M 47.34M 612M 47.25M 46.21M 1.94B